Curis (CRIS) Competitors $1.81 +0.10 (+5.85%) Closing price 04:00 PM EasternExtended Trading$1.82 +0.01 (+0.55%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS vs. FBIO, SABS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, BIIB, and INCYShould you be buying Curis stock or one of its competitors? The main competitors of Curis include Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and Incyte (INCY). These companies are all part of the "biotechnology" industry. Curis vs. Its Competitors Fortress Biotech SAB Biotherapeutics Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Incyte Fortress Biotech (NASDAQ:FBIO) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Do analysts rate FBIO or CRIS? Fortress Biotech presently has a consensus price target of $16.50, suggesting a potential upside of 359.61%. Curis has a consensus price target of $17.00, suggesting a potential upside of 839.23%. Given Curis' higher possible upside, analysts clearly believe Curis is more favorable than Fortress Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, FBIO or CRIS? Curis has lower revenue, but higher earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFortress Biotech$59.30M1.80-$46M-$1.05-3.42Curis$11.41M1.98-$43.39M-$4.88-0.37 Which has more volatility & risk, FBIO or CRIS? Fortress Biotech has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.81, suggesting that its stock price is 281% more volatile than the S&P 500. Do institutionals and insiders hold more shares of FBIO or CRIS? 96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 27.9% of Fortress Biotech shares are owned by insiders. Comparatively, 5.5% of Curis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer FBIO or CRIS? In the previous week, Fortress Biotech had 2 more articles in the media than Curis. MarketBeat recorded 2 mentions for Fortress Biotech and 0 mentions for Curis. Fortress Biotech's average media sentiment score of 0.56 beat Curis' score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the media. Company Overall Sentiment Fortress Biotech Positive Curis Neutral Is FBIO or CRIS more profitable? Fortress Biotech has a net margin of -24.84% compared to Curis' net margin of -341.24%. Curis' return on equity of 0.00% beat Fortress Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Fortress Biotech-24.84% -301.81% -27.48% Curis -341.24%N/A -102.22% SummaryFortress Biotech beats Curis on 9 of the 15 factors compared between the two stocks. Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.62M$3.14B$5.81B$10.03BDividend YieldN/A2.27%6.67%4.54%P/E Ratio-0.3721.4875.7526.29Price / Sales1.98233.25449.5181.86Price / CashN/A44.1225.7029.20Price / Book-2.5510.0511.506.43Net Income-$43.39M-$53.33M$3.28B$270.56M7 Day Performance10.37%2.18%1.30%3.01%1 Month Performance5.85%11.91%11.25%9.74%1 Year Performance-63.36%14.14%59.54%26.68% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.1077 of 5 stars$1.81+5.8%$17.00+839.2%-65.7%$22.62M$11.41M-0.3760Gap UpFBIOFortress Biotech3.0398 of 5 stars$2.58+6.6%$16.50+539.5%+103.4%$76.77M$57.67M-2.46170High Trading VolumeSABSSAB Biotherapeutics3.2943 of 5 stars$2.08-1.0%$11.00+428.8%-26.1%$21.66M$1.32M-0.52140Short Interest ↓BOLTBolt Biotherapeutics3.4835 of 5 stars$5.29-0.3%$47.50+798.8%-60.2%$9.85M$7.69M-0.2090Positive NewsGap DownAMGNAmgen4.7599 of 5 stars$287.71+0.7%$304.43+5.8%-12.6%$154.89B$33.42B23.5228,000Positive NewsGILDGilead Sciences4.945 of 5 stars$112.97+0.4%$115.39+2.1%+47.2%$140.17B$28.75B22.5017,600Positive NewsVRTXVertex Pharmaceuticals4.9653 of 5 stars$391.02-0.3%$497.10+27.1%-15.5%$100.25B$11.02B27.956,100Positive NewsREGNRegeneron Pharmaceuticals4.77 of 5 stars$580.70+0.2%$817.67+40.8%-50.6%$61.55B$14.20B14.6315,106Trending NewsALNYAlnylam Pharmaceuticals3.7932 of 5 stars$446.51-1.3%$405.33-9.2%+84.4%$58.53B$2.25B-180.772,230BIIBBiogen4.7534 of 5 stars$132.22-0.3%$185.74+40.5%-29.6%$19.39B$9.68B12.647,605Positive NewsINCYIncyte4.5994 of 5 stars$84.61+1.1%$81.60-3.6%+41.3%$16.52B$4.24B19.232,617Positive NewsShort Interest ↑ Related Companies and Tools Related Companies Fortress Biotech Competitors SAB Biotherapeutics Competitors Bolt Biotherapeutics Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors Incyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRIS) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
